Faculty of Physical Therapy, Cairo University
Dokki, 11432, Egypt
NCT Number: NCT06998147
Balance deficits, gait abnormalities, impaired cognitive function, psychological disturbances and disconnection from community are key characteristics of multiple sclerosis (MS). Thus, exploring the interrelationships and the primary risk factors related to clinical manifestations and consequences of MS is of definite clinical significance. The primary aims of the study are to evaluate the association interplay among balance, functional mobility, cognitive function, psychological well-being, and community participation in addition to identify the anticipated contributing factors that function as predictors of MS features.
Looking for future studies?
Notify Me18 year–60 year
Female
Observational
Dokki, 11432, Egypt
This cross-sectional study will be carried out on sixty-four patients with MS. Balance performance was evaluated by a standardized Berg Balance Scale (BBS). Functional mobility will be measured via the well validated Timed Up and Go (TUG) test. Patients᾽ cognitive functions will be assessed by the Montreal Cognitive Assessment (MoCA), which is a sensitive screening test for the diagnosis of mild cognitive impairment. The psychological well-being will be measured based on the Hospital Anxiety and Depression Scale (HADS), which is widely employed to evaluate mood disturbances in clinical settings. Furthermore, community participation and engagement constraints will be measured with the Community Integration Questionnaire (CIQ) as they clearly capture the extent of functional and social integration into the community.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Participants will be screened for inclusion criteria to guarantee sample homogeneity and clinical applicability. First, all subjects will be diagnosed with MS confirmed by a neurologist according to the revised McDonald criteria. These criteria have the highest sensitivity and specificity and therefore are considered the gold standard in MS diagnosis. Second, participants will be be aged at least 18 years, so as to be able, cognitively and legally, to engage in the study as an informed study volunteer. Third, relapse- and relapse related treatments should be stopped by at least 1 month before the assessment. This is crucial in order to maximize the control of the transient influence of aggravation of the symptoms on patients᾽ cognitive and motor performance. Fourth, individuals will be eligible to participate in the study if they can ambulate, either independently or with the use of assistive device, as the study includes physical performance measures such as balance and gait. Finally, the maximum EDSS-value will be below 6 (moderate disability) to ensure independence of gait without constant support, as this is necessary to ensure comparability of balance and cognitive function.
Exclusion criteria
-
to evaluate the association interplay among balance, functional mobility, cognitive function, psychological well-being, and community participation in addition to identify the anticipated contributing factors that function as predictors of MS features.
Time frame: this outcome will take from 7 o 10 days to be completely assessed in all patients
Balance performance was evaluated by a standardized Berg Balance Scale (BBS). scores ranges from 0 (no balance) to 54 (maximum balance)
Time frame: this outcome will take from 7 o 10 days to be completely assessed in all patients
Functional mobility will be measured via the well validated Timed Up and Go (TUG) test.
Time frame: this outcome will take from 5 to 7 days to be completely assessed in all patients
Patients᾽ cognitive functions will be assessed by the Montreal Cognitive Assessment (MoCA)
Time frame: this outcome will take from 5 to 7 days to be completely assessed in all patients
The psychological well-being will be measured based on the Hospital Anxiety and Depression Scale (HADS). It consists of 14 items, divided into two subscales: 7 items for anxiety
Time frame: this outcome will take from 5 to 7 days to be completely assessed in all patients
community participation and engagement constraints will be measured maximum total score of 30 points. A score of 26 or above is generally considered indicative of normal cognitive function. Scores between 18 and 25 suggest mild cognitive impairment, while scores from 10 to 17 indicate moderate cognitive impairment. A score below 10 reflects severe cognitive decline. According to MoCA guidelines, one point should be added to the total score for individuals with 12 years of education or less to account for the potential impact of educational background. Community Integration Questionnaire (CIQ)
Cairo University
Other
Investigating Predictive Associations Among Postural Balance, Functional Mobility, Cognitive Function and Psychological Well-being in Patients With Multiple Sclerosis: A Cross-Sectional Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07681037
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Merkez, Edirne, Turkey (Türkiye)
View Trial DetailsNCT05219201
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Roscoff, France
View Trial DetailsNCT07507149
Anxiety, Anxiety Disorders
Beirut, Lebanon
View Trial DetailsNCT02468765
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Lille, Hauts-de-France, France
View Trial Details